The hospital pharmacist slid three bottles of pills across the counter, gave my wife a form to sign, and reminded her that this was not the corner drugstore. The pharmacy knew how many pills had been dispensed, he said; it would know how many had been consumed; and it would expect her to return the unused pills before she left the country. The pharmacist made it clear that he was not only in touch with our doctor but with the company supplying the medication. They would know if she broke the rules.
LATEST EFGC NEWS
As of Wednesday, July 1, 2015, the Illinois General Assembly and Governor Rauner had failed to agree to an Illinois budget for the 2016 fiscal year. As a result, statewide funding for epilepsy ceased, the Epilepsy Resource Center in Springfield closed its doors forever and other Illinois epilepsy organizations, including the Epilepsy Foundation of Greater Chicago, began to implement plans to cut staff and reduce epilepsy programs and services.
PhRMA and the Epilepsy Foundation report more than 400 medicines in development to treat neurological disorders
America’s biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer’s disease, multiple sclerosis (MS) and Parkinson’s disease. As highlighted in a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Epilepsy Foundation, scientists around the globe are collaborating to find new or more effective treatments for patients with these complex disorders that attack the nervous system.
Eisai Announces FDA Approval of New Indication for Primary Generalized Tonic-Clonic (PGTC) Seizures in Patients with Epilepsy Age 12 and Older
Eisai Inc. announced on June 22nd, 2015, that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII for adjunctive therapy in the treatment of primary generalized tonic-clonic (PGTC) seizures in patients age 12 and older. FYCOMPA, the first and only FDA-approved non-competitive AMPA receptor antagonist, was initially approved in October 2012 as adjunctive treatment for partial-onset seizures, with or without secondarily generalized seizures, in patients with epilepsy age 12 and older.
Join us on Saturday, June 6th as we partner with Americans for Safe Access – Illinois to present the Illinois Medical Cannabis Patient Summit. This summit will provide education to Illinois residents regarding medical cannabis and its benefits, medicating with cannabis and how to participate in the Illinois Medical Cannabis Pilot Program. Additional information to help Veterans navigate the VHA system as a medical cannabis patient will be presented the same evening from 6:00pm until 8:30pm.
llinois’ medical marijuana law went into effect January 1, 2014, but so far, not a single patient has received treatment under the pilot program. What’s happening? And with us so far into the test period and not generating any data, how will we know that the program is effective?